Article
Itaconate delays type 2 diabetes progression by alkylating RIPK3 to inhibit pancreatic β‑cell failure
2026-08-10
Abstract excerpt
<title>Abstract</title> <p>Dysregulated glucose and lipid metabolism drives β-cell failure, a central event in type 2 diabetes (T2D) pathogenesis; however, effective mechanisms to preserve β-cell mass remain elusive. Through comprehensive metabolomic profiling of human serum, we identified itaconate as a novel metabolic biomarker reduced in T2D patients in a disease severity–dependent manner. Genetic ablation of...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 597e460d-5a8e-58d3-8801-6b44bd7cf39a
- DOI
- 10.21203/rs.3.rs-10537918/v1
